

Daiichi Sankyo initiates clinical trial of DS-7300 in collaboration with Sarah Cannon Research Institute

This article was originally published [here](#)

The study is the first in the strategic oncology partnership announced between Daiichi Sankyo and Sarah Cannon, designed to expedite and optimize global clinical development of Daiichi Sankyo's

The post [Daiichi Sankyo initiates clinical trial of DS-7300 in collaboration with Sarah Cannon Research Institute](#) appeared first on [Pharmaceutical Business review](#).